Genitourinary Cancers | Clinical

TAK-700 Achieves Limited Overall Survival Improvement in mHSPC

June 08, 2021

Data from the phase 2 the phase 3 SWOG S1216 presented during the ASCO Annual Meeting shows numerical overall survival improvement with he experimental combination that missed the threshold for statistical significance.

Urothelial Cancer Guidelines Are Updated to Include Immune Checkpoint Inhibitors

May 17, 2021

Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines